These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 22759740)

  • 1. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
    Ratner ES; Sartorelli AC; Lin ZP
    Curr Opin Oncol; 2012 Sep; 24(5):564-71. PubMed ID: 22759740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
    Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
    Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
    Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
    Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
    Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y; Du H
    Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
    Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
    BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
    Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
    Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
    Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
    J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.